Abstrakt
Adult maintenance hemodialysis (MHD) patients experience high mortality and morbidity and poor quality of life (QoL). Markers of protein-energy wasting are associated with these poor outcomes. The OPPORTUNITY™ Trial examined whether recombinant human growth hormone (hGH) reduces mortality in hypoalbuminemic MHD patients. Secondary end points were effects on number of hospitalizations, cardiovascular events, lean body mass (LBM), serum proteins, exercise capacity, QoL and adverse events.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Nephrology, Dialysis, Transplantation |
Vol/bind | 26 |
Udgave nummer | 12 |
Sider (fra-til) | 4095-103 |
Antal sider | 9 |
ISSN | 0931-0509 |
DOI | |
Status | Udgivet - 2011 |